Compare Ascendis Pharma A/S (ASND) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Goldman Sachs Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Goldman Sachs Group Inc trades at $1,060.56 (market cap $311.29B). The key difference: Goldman Sachs Group Inc is far larger — about 17.5× Ascendis Pharma A/S's market cap, and Goldman Sachs Group Inc pays a 1.71% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GS | |
|---|---|---|
Market Cap | $17.74B | $311.29B |
Sector | Health | Financials |
52-Week High | $277.18 | $1.11K |
52-Week Low | $163.32 | $700.41 |
Enterprise Value | $18.11B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Goldman Sachs (GS) trades at $1,055.18, down 0.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $17.55 surpassing expectations of $16.47. Revenue grew to $58.28 billion in 2025, and net income margin improved to 29.89%. Recent news highlights GS's role in leading high-profile IPOs like Anthropic, signaling robust investment banking activity. The stock is near its pivot point of $1,055, with support at $1,045 and resistance at $1,065.
The outlook for GS is positive, driven by earnings momentum and a favorable IPO pipeline, but risks include volatile cash flows and macroeconomic sensitivity. Analyst consensus is a Buy with a price target of $1,080, indicating potential upside. Investors should monitor execution in investment banking and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
